학술논문

Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis
Document Type
article
Source
International Journal of Ophthalmology, Vol 13, Iss 5, Pp 806-815 (2020)
Subject
anti-vascular endothelial growth factor
bevacizumab
laser therapy
meta-analysis
retinopathy of prematurity
recurrence
ranibizumab
Ophthalmology
RE1-994
Language
English
ISSN
2222-3959
2227-4898
Abstract
AIM: To compare the efficacy and safety between laser therapy and anti-vascular endothelial growth factor (VEGF) agents intravitreal injection monotherapy in type-1 retinopathy of prematurity (ROP) and aggressive posterior retinopathy of prematurity (APROP). METHODS: A systematic literature search was performed in PubMed, Cochrane Library, and Embase for original comparable studies. We included studies that compare laser therapy and intravitreal injections of anti-VEGF agents monotherapy in ROP regardless of languages and publication types. RESULTS: Complication incidence was significantly higher in laser therapy group (OR: 0.38; 95%CI: 0.19-0.75; P=0.005). Spherical equivalent (SE) was higher in laser therapy [weighted mean difference (WMD): 2.40, 95%CI: 0.88-3.93; P=0.002]. The time between treatment and retreatment was longer in laser therapy group (WMD: 8.45, 95%CI: 5.35-11.55; P